Shots:
- Takeda exercises its option to acquire GammaDelta which includes up front along with development and regulatory milestones. The acquisition is expected to be close in Q1’22
- The acquisition follows a 2017 collaboration b/w Takeda & GammaDelta to develop GammaDelta’s novel γδ T cell therapy platforms. Takeda will obtain GammaDelta’s allogeneic Vδ1 gamma-delta (γδ) T cell therapy platforms including both blood-derived and tissue-derived platforms in addition to early-stage cell therapy programs
- The acquisition will bolster Takeda’s immuno-oncology and innate immune cell therapy portfolio with the addition of γδ T cell therapy platforms for solid tumors & hematological malignancies
Click here to read full press release/ article | Ref: Takeda | Image: GeneOnline
The post Takeda to Acquire GammaDelta to Advance the Development of Allogeneic γδT Cell Therapies for the Treatment of Solid Tumors first appeared on PharmaShots.
